Ticker Symbol: CUR
QUEBEC CITY, March 21, 2012 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, announced today that the Company will release its first quarter results on March 30, 2012, before stock markets open. At 11:30 a.m. (EST) the same day, management will hold a conference call with investors to discuss these results.
Investors and financial analysts wishing to participate in the "DiagnoCure Q1 2012 Earnings Announcement" conference call shall dial the toll-free number 1-888-231-8191, and provide the conference ID number: 61577555.
The event will also be webcasted live on DiagnoCure's website at www.diagnocure.com, through the hyperlink under the "Presentations" page of the "Investors" tab. A replay of the audio conference will be available on April 4, 2012.
Annual Meeting of Shareholders
Shareholders are reminded that DiagnoCure's Annual Meeting will be held, as follows:
|TIME:||Friday, March 30, 2012||LOCATION:||Auberge Saint-Antoine|
|2:00 p.m. (EST)||8 Saint-Antoine Street|
On this occasion, Dr. Yves Fradet, President and Chief Medical Officer, and Chantal Miklosi, Chief Financial Officer will take the opportunity to review the financial highlights and performance of the fiscal year ended October 31, 2011.
DiagnoCure (TSX: CUR) is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Company launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in June 2011. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. The PROGENSA® PCA3 test is commercialized in Europe under CE mark and is now approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.
For further information:
Chief Financial Officer
Morin Public Relations
(514) 289-8688 ext. 236